tetano
Editor, Senior Moderator
Infection
. 2024 May 18.
doi: 10.1007/s15010-024-02292-z. Online ahead of print. Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study
Hans-Jakob Meyer[SUP] 1 2 [/SUP], Lukas Mödl[SUP] 3 [/SUP], Olesya Unruh[SUP] 4 [/SUP], Weiwei Xiang[SUP] 1 [/SUP], Sarah Berger[SUP] 1 [/SUP], Moritz Müller-Plathe[SUP] 1 [/SUP], Gernot Rohde[SUP] 4 5 6 [/SUP], Mathias W Pletz[SUP] 4 7 [/SUP], Jan Rupp[SUP] 4 8 [/SUP], Norbert Suttorp[SUP] 1 4 9 [/SUP], Martin Witzenrath[SUP] 1 4 9 [/SUP], Thomas Zoller[SUP] 1 [/SUP], Mirja Mittermaier[SUP] #[/SUP][SUP] 1 10 [/SUP], Fridolin Steinbeis[SUP] #[/SUP][SUP] 11 [/SUP]; CAPNETZ study group
Collaborators, Affiliations
Purpose: Coronavirus disease 2019 (COVID-19) and non-COVID-19 community-acquired pneumonia (NC-CAP) often result in hospitalization with considerable risks of mortality, ICU treatment, and long-term morbidity. A comparative analysis of clinical outcomes in COVID-19 CAP (C-CAP) and NC-CAP may improve clinical management.
Methods: Using prospectively collected CAPNETZ study data (January 2017 to June 2021, 35 study centers), we conducted a comprehensive analysis of clinical outcomes including in-hospital death, ICU treatment, length of hospital stay (LOHS), 180-day survival, and post-discharge re-hospitalization rate. Logistic regression models were used to examine group differences between C-CAP and NC-CAP patients and associations with patient demography, recruitment period, comorbidity, and treatment.
Results: Among 1368 patients (C-CAP: n = 344; NC-CAP: n = 1024), C-CAP showed elevated adjusted probabilities for in-hospital death (aOR 4.48 [95% CI 2.38-8.53]) and ICU treatment (aOR 8.08 [95% CI 5.31-12.52]) compared to NC-CAP. C-CAP patients were at increased risk of LOHS over seven days (aOR 1.88 [95% CI 1.47-2.42]). Although ICU patients had similar in-hospital mortality risk, C-CAP was associated with length of ICU stay over seven days (aOR 3.59 [95% CI 1.65-8.38]). Recruitment period influenced outcomes in C-CAP but not in NC-CAP. During follow-up, C-CAP was linked to a reduced risk of re-hospitalization and mortality post-discharge (aOR 0.43 [95% CI 0.27-0.70]).
Conclusion: Distinct clinical trajectories of C-CAP and NC-CAP underscore the need for adapted management to avoid acute and long-term morbidity and mortality amid the evolving landscape of CAP pathogens.
Keywords: COVID-19; Community-acquired pneumonia; Observational cohort study; SARS-CoV-2.
. 2024 May 18.
doi: 10.1007/s15010-024-02292-z. Online ahead of print. Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study
Hans-Jakob Meyer[SUP] 1 2 [/SUP], Lukas Mödl[SUP] 3 [/SUP], Olesya Unruh[SUP] 4 [/SUP], Weiwei Xiang[SUP] 1 [/SUP], Sarah Berger[SUP] 1 [/SUP], Moritz Müller-Plathe[SUP] 1 [/SUP], Gernot Rohde[SUP] 4 5 6 [/SUP], Mathias W Pletz[SUP] 4 7 [/SUP], Jan Rupp[SUP] 4 8 [/SUP], Norbert Suttorp[SUP] 1 4 9 [/SUP], Martin Witzenrath[SUP] 1 4 9 [/SUP], Thomas Zoller[SUP] 1 [/SUP], Mirja Mittermaier[SUP] #[/SUP][SUP] 1 10 [/SUP], Fridolin Steinbeis[SUP] #[/SUP][SUP] 11 [/SUP]; CAPNETZ study group
Collaborators, Affiliations
- PMID: 38761325
- DOI: 10.1007/s15010-024-02292-z
Purpose: Coronavirus disease 2019 (COVID-19) and non-COVID-19 community-acquired pneumonia (NC-CAP) often result in hospitalization with considerable risks of mortality, ICU treatment, and long-term morbidity. A comparative analysis of clinical outcomes in COVID-19 CAP (C-CAP) and NC-CAP may improve clinical management.
Methods: Using prospectively collected CAPNETZ study data (January 2017 to June 2021, 35 study centers), we conducted a comprehensive analysis of clinical outcomes including in-hospital death, ICU treatment, length of hospital stay (LOHS), 180-day survival, and post-discharge re-hospitalization rate. Logistic regression models were used to examine group differences between C-CAP and NC-CAP patients and associations with patient demography, recruitment period, comorbidity, and treatment.
Results: Among 1368 patients (C-CAP: n = 344; NC-CAP: n = 1024), C-CAP showed elevated adjusted probabilities for in-hospital death (aOR 4.48 [95% CI 2.38-8.53]) and ICU treatment (aOR 8.08 [95% CI 5.31-12.52]) compared to NC-CAP. C-CAP patients were at increased risk of LOHS over seven days (aOR 1.88 [95% CI 1.47-2.42]). Although ICU patients had similar in-hospital mortality risk, C-CAP was associated with length of ICU stay over seven days (aOR 3.59 [95% CI 1.65-8.38]). Recruitment period influenced outcomes in C-CAP but not in NC-CAP. During follow-up, C-CAP was linked to a reduced risk of re-hospitalization and mortality post-discharge (aOR 0.43 [95% CI 0.27-0.70]).
Conclusion: Distinct clinical trajectories of C-CAP and NC-CAP underscore the need for adapted management to avoid acute and long-term morbidity and mortality amid the evolving landscape of CAP pathogens.
Keywords: COVID-19; Community-acquired pneumonia; Observational cohort study; SARS-CoV-2.